Holdings derived from the most recent reported transactions. Not adjusted for stock splits or share-class conversions.
| Issuer | Shares | Source | Last tx | Detail |
|---|---|---|---|---|
| Apellis Pharmaceuticals, Inc. | 3,579,305 | reported | 13 Nov 2017 | tx 4+3,579,305−7,362,669 |
| Akero Therapeutics, Inc. | 3,033,552 | reported | 06 Jul 2020 | tx 7−211,467 |
| Checkmate Pharmaceuticals, Inc. | 2,287,580 | reported | 12 May 2022 | tx 9−437,604 |
| IMPEL NEUROPHARMA INC | 0 | reported | 27 Apr 2021 | tx 8+2,759,791−36,157,791 |
| VYNE Therapeutics Inc. | 0 | reported | 29 Jan 2018 | tx 3+1,461,552−3,227,700 |
| Date | Type | Issuer | Qty | Price | Signals |
|---|---|---|---|---|---|
| 10 May 2022 | SALE | Checkmate Pharmaceuticals, Inc. | 18,676 | 10.38 USD | |
| 11 May 2022 | SALE | Checkmate Pharmaceuticals, Inc. | 17,700 | 10.38 USD | |
| 12 May 2022 | SALE | Checkmate Pharmaceuticals, Inc. | 124,525 | 10.39 USD | |
| 05 May 2022 | SALE | Checkmate Pharmaceuticals, Inc. | 20,743 | 10.37 USD | |
| 06 May 2022 | SALE | Checkmate Pharmaceuticals, Inc. | 48,334 | 10.37 USD | |
| 09 May 2022 | SALE | Checkmate Pharmaceuticals, Inc. | 17,600 | 10.37 USD | |
| 27 Apr 2022 | SALE | Checkmate Pharmaceuticals, Inc. | 47,396 | 10.38 USD | |
| 29 Apr 2022 | SALE | Checkmate Pharmaceuticals, Inc. | 69,230 | 10.38 USD | |
| 28 Apr 2022 | SALE | Checkmate Pharmaceuticals, Inc. | 73,400 | 10.38 USD | |
| 27 Apr 2021 | PURCHASE | IMPEL NEUROPHARMA INC | 450,000 | 15.00 USD | first after silence |
| 27 Apr 2021 | CONVERSION | IMPEL NEUROPHARMA INC | 2,309,791 | — | |
| 27 Apr 2021 | CONVERSION | IMPEL NEUROPHARMA INC | 5,876,034 | 0.00 USD | deriv |
| 27 Apr 2021 | CONVERSION | IMPEL NEUROPHARMA INC | — | 0.00 USD | deriv |
| 27 Apr 2021 | CONVERSION | IMPEL NEUROPHARMA INC | 13,233,885 | 0.00 USD | deriv |
| 27 Apr 2021 | CONVERSION | IMPEL NEUROPHARMA INC | 8,201,930 | 0.00 USD | deriv |
| 27 Apr 2021 | CONVERSION | IMPEL NEUROPHARMA INC | 8,845,942 | 0.00 USD | deriv |
| 22 Apr 2021 | OTHER | IMPEL NEUROPHARMA INC | — | 0.00 USD | deriv |
| 06 Jul 2020 | SALE | Akero Therapeutics, Inc. | 4,603 | 33.83 USD | |
| 01 Jul 2020 | SALE | Akero Therapeutics, Inc. | 108,064 | 34.45 USD | |
| 02 Jul 2020 | SALE | Akero Therapeutics, Inc. | 3,800 | 33.63 USD | |
| 06 Feb 2020 | SALE | Akero Therapeutics, Inc. | 6,102 | 27.03 USD | |
| 08 Jan 2020 | SALE | Akero Therapeutics, Inc. | 15,677 | 19.86 USD | |
| 06 Jan 2020 | SALE | Akero Therapeutics, Inc. | 42,221 | 19.64 USD | |
| 07 Jan 2020 | SALE | Akero Therapeutics, Inc. | 31,000 | 20.17 USD | |
| 25 Jan 2018 | PURCHASE | VYNE Therapeutics Inc. | 265,000 | 17.00 USD |
1 purchase reported after at least 12 months of silence — most recent on 27 Apr 2021.